Sema Karabudak

Sema Karabudak

Auto-generated profile, based on publicly available information

Sema Karabudak

Ankara Yildirim Beyazit Universitesi

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2022 in Nevşehir Bilim ve Teknoloji Dergisi
Verified
Journal Article
Closed access
SKSema Karabudak
Sema Karabudak
MAMeryem Sena AKKUS
Meryem Sena AKKUS
Yeni nesil dizileme (YND) araçları, büyük miktarda veri üretme kapasitesine sahiptir ancak dizileme sonrası büyük ölçekli veri analizi için yeterli olmayan hesaplama ve depolama kapasitesi ile donatılmışlardır. Bulut bilişim altyapılarını kullanmak YND verilerinin analizi, depolanması ve aktarılması ile ilgili sorunlara alternatif bir seçenek olmuştur. Bulut bilişim, kullanıcılara dizileme verilerinin analizi için gerekli hesaplama kapasitesi ve bilişim altyapılarına erişim sunmakta ve biyoinformatik altyapıları için gerekli olan ön sermaye harcamalarının çoğunu ortadan kaldırmaktadır. Yapılan bu çalışmada yeni nesil dizileme yöntemi ve dizileme verilerinin analizinde kullanılan bulut bilişim platformaları hakkında bilgi verilmiştir.

30 October 2026 in Fabad Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SKSema Karabudak
Sema Karabudak
Sumeyye AltunokSumeyye Altunok
Sumeyye Altunok
EBEmre Can Buluz
Emre Can Buluz
Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tuberculosis), remains one of the leading causes of mortality from infectious diseases worldwide, underscoring the urgent need for more effective vaccine strategies. Advances in immunoinformatics have enabled rational, cost-effective vaccine design through systematic epitope identification and optimization. In this study, a multi-epitope vaccine candidate was computationally designed by integrating cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and B-cell epitopes derived from three M. tuberculosis antigens associated with distinct stages of infection: Ag85B, ESAT-6, and HspX. Selected epitopes were screened for antigenicity, immunogenicity, allergenicity, toxicity, and global population coverage, and assembled into a single construct using rational linker and adjuvant strategies. Structural modeling and refinement were performed, followed by molecular docking and molecular dynamics simulations to evaluate interactions with human Toll-like receptors (TLRs) TLR2, TLR4, and TLR9. The designed construct exhibited favorable antigenic and safety profiles, structural stability, and broad population coverage. Docking, molecular dynamics, and binding free-energy analyses suggested stable and energetically favorable interactions with all three TLRs, with the strongest binding observed for the TLR9 complex. In silico immune simulations predicted robust cellular and humoral immune responses, characterized by elevated interferon-γ (IFN-γ) and interleukin-2 (IL-2) levels and the formation of immunological memory. Overall, this study presents a stage-spanning, multi-epitope TB vaccine design and provides a comprehensive immunoinformatics framework that supports further experimental validation and optimization.